RxDoctor Payments Data

Juan Esnard, MD

Interventional Cardiology · Macon, GANPI 1225088289

Payments from drug & device makers

$3,014in general payments, 2019–2025

Across 43 payments — averaging $70.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Shockwave Medical, Inc$150
  • Boston Scientific$132
  • Teleflex LLC$106
  • AstraZeneca$96
  • Kestra Medical Technology Services, Inc.$72
  • plus $255 from 7 others

What the payments were for

  • Travel & lodging$1,38146%
  • Food & beverage$1,58753%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,014 in reported general payments places this provider in the 15th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$197,659
Medicare patients
1,120
Services billed
2,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$183,975
EntrestoSacubitril/Valsartan78$63,426
XareltoRivaroxaban51$42,653
Repatha SureclickEvolocumab33$20,694
MultaqDronedarone Hcl26$17,013
Metoprolol Succinate262$2,844
ClopidogrelClopidogrel Bisulfate281$2,641
Ranolazine ErRanolazine37$2,626
Atorvastatin Calcium296$2,195
Acebutolol Hcl17$1,639
Losartan Potassium116$1,498
Isosorbide Mononitrate ErIsosorbide Mononitrate78$1,081
Prasugrel Hcl17$969
Carvedilol148$910
Rosuvastatin Calcium70$763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$183,975224 claims
NovartisEntresto$31$63,42678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →